TTY Biopharm Company Limited (4105.TWO) - Deep Dive Research Report

Taipei Exchange listed | Healthcare / Specialty Pharmaceuticals | Report date: 2026-06-08

1. What the company does

TTY Biopharm makes hard-to-make medicines. Strip away the corporate language and that is the whole business: the company takes drugs that other generic manufacturers cannot easily copy - injectable cancer therapies, liposome-encapsulated antibiotics, sterile critical-care products - and it manufactures them to a quality that wins hospital tenders and, increasingly, foreign regulatory approval. It also acts as the Taiwanese commercial home for foreign innovator oncology drugs that need a local partner to navigate Taiwan's national health insurance system. In a country where most pharma companies fight over commoditized oral tablets, TTY built its franchise on the parts of the medicine cabinet that are technically difficult and lightly contested.

The company sits at the centre of Taiwan's oncology and critical-infection drug supply. In plain terms: if a Taiwanese hospital is treating a cancer patient or a patient with a severe fungal or bacterial infection in the ICU, there is a meaningful chance the drug being infused was made or supplied by TTY.

The founding story matters because the company you see today is the product of two reinventions. TTY was founded in 1960 by Chang Tien-te (張天德). By the early 1990s it was near bankruptcy. In 1994 a group of investors led by Lin Jung-chin (林榮錦), together with Hsiao Ying-chun (蕭英鈞) and other partners, took stakes in the failing company at Chang's invitation, with Lin running operations as general manager. Over the next two decades Lin pushed TTY away from ordinary generics and toward "difficult generics" (困難學名藥) - drugs that are technically demanding to formulate, especially injectables and liposomal products. That bet built the niche TTY still occupies. Lin's tenure ended in controversy: he was later accused in an embezzlement case of, among other things, licensing thirteen of TTY's cancer and CNS drug patents to a Swiss entity (Inopha AG) without compensation, and of diverting the signing and milestone fees from a 2011 Johnson & Johnson contract-manufacturing deal away from TTY and to Inopha (Mirror Media, 2020; Business Today, 2020). Lin departed and went on to lead the CenterLab (晟德) group. The company then installed Lin Chuan (林全) - a former Premier of Taiwan - as chairman, a striking governance signal for a mid-cap drugmaker and a deliberate move toward institutional respectability after the founder-era turmoil.

The core value proposition has two halves. To Taiwanese hospitals and physicians, TTY offers a reliable domestic supply of high-acuity drugs - the kind where a stock-out is a clinical emergency - backed by EU- and FDA-grade manufacturing. To foreign innovators, TTY offers a turnkey route into Taiwan: regulatory filing, NHI reimbursement negotiation, and an established oncology salesforce that already calls on every major cancer centre.

The technical heart of the business is drug-delivery formulation, specifically liposome and microsphere technology. A liposome is a microscopic fatty bubble that carries a drug, changing how the drug distributes in the body - reducing toxicity, extending circulation, or concentrating the drug at the tumour. Making liposomal injectables reproducibly, at sterile scale, and to a standard that passes EU and US inspection is genuinely hard; it is closer to a manufacturing science than a chemistry recipe, and it is the moat that separates TTY from the tablet-pressing generic crowd.

A concrete example: Lipo-AB, TTY's liposomal amphotericin B. Amphotericin B is an old, powerful but kidney-toxic antifungal used in critically ill patients. Encapsulating it in a liposome blunts the toxicity. TTY manufactures its own version, secured US FDA approval, and now sells it into the United States, where management says it has captured more than a third of the market. That single product is the proof-of-concept for the entire international strategy: take a TTY-made difficult injectable, get it approved in a regulated Western market, and let manufacturing quality - not price alone - win share.

2. Business segments

TTY reports through five business units. The revenue-mix percentages below are drawn from the Q1 2026 investor conference (2026-05-27) segment disclosure and are representative of the current shape of the group.

2.1 Oncology Business Unit (TOT) - ~40% of revenue

This is the company's largest and defining segment, established in 2000. It does three things at once: it sells TTY's own difficult-to-make oncology injectables (liposomal doxorubicin, generic taxanes, platinum agents, irinotecan, gemcitabine); it in-licenses and commercializes foreign innovator cancer drugs for the Taiwan market; and it pursues newer modalities through partnerships.

What it knows how to do that others don't is run a sterile oncology injectable line and an oncology salesforce simultaneously. The manufacturing competence (liposomes, cytotoxic injectables) and the commercial competence (a salesforce credentialed with every major Taiwanese oncologist) reinforce each other - the factory gives the salesforce a differentiated own-brand portfolio, and the salesforce gives foreign innovators a reason to pick TTY as their Taiwan partner. That two-sided position took two decades to build.

Its competitive position in Taiwan is strong; management states TTY ranks in the top tier of Taiwanese oncology pharma. The in-licensed portfolio has been refreshed aggressively: Yondelis (trabectedin), Pemazyre (pemigatinib, an FGFR inhibitor), Minjuvi (tafasitamab, for lymphoma, which secured NHI reimbursement at end-2025), and Xpovio (selinexor, for multiple myeloma, distribution rights obtained) sit alongside the legacy own-brand generics. This is the group's primary engine and the focus of management attention.

2.2 Critical Care / Intensive Care Business Unit (TIC) - ~18% of revenue

This unit supplies anti-infectives and ICU drugs: colistin (Colimycin), daptomycin (Cubicin, in-licensed), the flagship liposomal amphotericin B (Lipo-AB), and a range of injectable antibiotics (Brosym, Maxtam, Cepiro). It also carries the newly launched antibiotic Bobimixyn, which management has repeatedly flagged as a fast-ramping back-line treatment.

The core capability overlaps with oncology - sterile injectable manufacturing - which is why the two units share a factory base. What distinguishes TIC is its position in the antibiotic supply-resilience story: governments and hospitals increasingly worry about dependence on imported antibiotics, and a domestic maker of critical injectables is strategically valuable. Lipo-AB is the segment's crown jewel and the spearhead of the export business, so this unit straddles domestic critical care and the international growth thesis.

2.3 Export & CDMO Business Unit - ~20% of revenue

This is the growth bet. It does two related things: it exports TTY-made difficult generics (chiefly Lipo-AB and self-produced arsenic trioxide) to regulated markets, and it offers contract development and manufacturing (CDMO) using TTY's liposome and microsphere platforms. The Chung-Li (中壢) factory became the first plant in Taiwan to pass EU GMP inspection (2009); the company's self-produced arsenic trioxide secured FDA approval with first US shipment in early 2023.

Why it exists separately: the economics and customers are entirely different from domestic hospital sales. Export revenue depends on foreign regulatory approvals and distributor relationships; CDMO revenue depends on landing manufacturing contracts from international pharma that lack liposome capability. Management has repeatedly framed this unit as the multi-year compounding story - the individual-company export ratio rose from 13.7% in 2024 to 18.8% by Q3 2025 (Q3 2025 conference, 2025-11-26), with a stated target above 20%.

Its competitive position rests on scarcity: there are few contract manufacturers anywhere that can make liposomal sterile injectables to FDA standard, and TTY is one of them. It wins on capability and quality certification rather than price. Where it loses is scale - it competes for CDMO mandates against far larger global players, and revenue is lumpy and approval-dependent.

2.4 Other / Investments Business Unit - ~19% of revenue

This segment captures agency products - notably the imported influenza vaccines (Agrippal, Flucelvax) where TTY has expanded from public-tender supply into the self-pay branded market and is targeting adjuvanted vaccines for the elderly - and the contribution of consolidated subsidiaries. The vaccine business is seasonal and tender-driven; it gives TTY a recurring, high-visibility public-health franchise but at lower differentiation than its injectables. The Oka-strain varicella vaccine (OkaBIK) was positioned to bid for Taiwan's public vaccination programme in Q4 2025 with potential deliveries from Q4 2026 (Q1 2025 conference, 2025-05-27).

2.5 Healthcare Business Unit - ~3% of revenue

The smallest unit, selling consumer-adjacent health products: digestive aids and antacids (Algitab, Alginos), calcium and osteoporosis products (Bio-Cal Plus), and metabolic products (Sulfin). It is a stable, low-growth contributor and not a strategic priority. It exists largely as a pharmacy-channel and brand-extension franchise rather than a technology play.

Segment summary

3. Products and business detail

Oncology catalogue. The own-brand and generic oncology line is broad: Lipo-Dox (liposomal doxorubicin, the flagship liposomal product), Gemmis (gemcitabine), Oxalip (oxaliplatin), Irino (irinotecan), Epicin (epirubicin), Folina (folinic acid/leucovorin), UFUR and TS-1 (oral fluoropyrimidine regimens), Megest (megestrol), Painkyl (fentanyl for cancer pain), Zobonic (zoledronic acid for bone metastases), and Episil (an oral mucositis device for chemotherapy side-effects). On top of these sit the in-licensed innovator drugs - Yondelis, Pemazyre, Minjuvi, Xpovio - and the latest own-development launch, Pulmivex (a domestic lung-cancer product launched January 2026). Self-produced arsenic trioxide (used in acute promyelocytic leukaemia) is both a domestic product and an export/FDA showcase.

Critical care and anti-infection catalogue. Lipo-AB (liposomal amphotericin B), Colimycin (colistin), Cubicin (daptomycin), Brosym, Maxtam, Cepiro, Metacin, Flusine, plus the newly launched antibiotic Bobimixyn. The influenza vaccines Agrippal and Flucelvax are carried as agency products.

Healthcare catalogue. Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, Sulfin.

What makes the products hard to make. The defining capability is sterile injectable and liposomal manufacturing. A liposomal injectable must be produced under aseptic conditions, with the drug correctly encapsulated, the particle size tightly controlled batch-to-batch, and the whole process validated to a regulator's satisfaction. The barrier is not the molecule - amphotericin B and doxorubicin are old, off-patent drugs - it is reproducing the delivery system at scale and passing inspection. TTY also runs microsphere technology (slow-release injectable depots), a second hard-to-replicate platform that underpins the CDMO pitch.

Certifications and process knowledge. The franchise is built on regulatory credentials. The Chung-Li factory was the first in Taiwan to clear EU GMP (2009); the arsenic trioxide line cleared US FDA (2022-23). These approvals are slow, expensive, and inspection-gated, and they are precisely what lets TTY export rather than just supply Taiwan.

Geographies. TTY markets products in more than 18 countries. The export priority markets are the United States (Lipo-AB, >1/3 share per management; arsenic trioxide), South Korea (continued growth), and a pipeline of new entries - Australia (regulatory approval pending), the Middle East, Southeast Asia and Vietnam - flagged in the FY2025 conference (2026-03-25). The company has built distribution subsidiaries across Southeast Asia (see subsidiary structure below).

Subsidiary structure. TTY consolidates and holds stakes in: TSH Biopharm / 東生華 (8403, 56.48% - listed, cardiovascular and gastrointestinal drugs); PharmaEngine / 智擎 (4162, 19.29% - listed; developer of the liposomal irinotecan product Onivyde, licensed to Ipsen/Servier); 創益生技 (27.84%); 榮港生技 (100%); and 美台生技 distribution arms in Thailand (40%), the Philippines (87%) and Vietnam (100%). The PharmaEngine stake is strategically notable - it ties TTY into the global liposomal-irinotecan franchise, reinforcing the liposome identity that runs through the whole group.

Milestones that changed the business: the 1994 recapitalisation and pivot to difficult generics; the 2000 launch of the oncology unit; the 2009 EU GMP clearance at Chung-Li (the export licence-to-operate); the 2022-23 FDA arsenic trioxide approval and first US shipment; and the multi-year Lipo-AB US share gain that validated the export model.

4. Customers

Who buys. The dominant customer is the Taiwanese hospital system - medical centres and regional hospitals, purchasing through tenders and through the National Health Insurance (NHI) reimbursement framework. For oncology and critical care, the practical buyers are hospital pharmacy committees and the treating physicians (oncologists, infectious-disease and ICU specialists) who drive formulary inclusion. For the export and CDMO unit, customers are foreign distributors (in the US, Korea, and emerging markets) and international pharma companies seeking liposome contract manufacturing. For vaccines, the buyer is the public sector (government tenders) plus, increasingly, self-pay consumers through clinics.

How the buying decision is made. In Taiwan, two gates matter: NHI listing (which sets reimbursement and effectively determines whether a hospital will stock a drug) and the hospital tender. For a difficult injectable, physicians care about clinical reliability and consistent supply far more than marginal price - a chemotherapy or antifungal stock-out is dangerous. The sales cycle for an in-licensed innovator drug is long, gated by regulatory approval and NHI price negotiation that can run for many months (the Minjuvi reimbursement that landed at end-2025 is an example of that multi-quarter cadence). For export, the cycle is even longer and approval-gated.

Why they choose TTY. Domestic security of supply from an EU/FDA-grade local manufacturer; a deep, credentialed oncology salesforce; and a one-stop relationship for foreign innovators who need Taiwan regulatory, reimbursement and commercial execution in a single partner. For export and CDMO customers the reason is starker: very few manufacturers can make the liposomal product at all.

Switching costs. Higher than they look. Hospital formulary changes for high-acuity injectables require physician comfort and re-qualification; for export products the customer is locked in by the regulatory dossier - the approval is filed against TTY's specific manufacturing site, so a buyer cannot trivially swap suppliers without a new regulatory process. For in-licensed drugs, the innovator is tied to TTY for the life of the local registration.

Concentration and contract structure. Revenue is spread across many hospital accounts and a broad product catalogue rather than a few named customers, which reduces single-customer risk on the domestic side. The mix is part recurring (NHI-reimbursed hospital demand, predictable), part tender-driven (vaccines, lumpy and seasonal), and part approval-dependent (export/CDMO, lumpy). In-licensing deals are long-term distribution agreements. The blend gives the domestic core reasonable predictability while the export/CDMO growth layer is inherently steppy.

5. Competitive landscape

The Taiwanese pharma industry is crowded at the commodity end and thin at the technical end, and TTY has deliberately positioned itself at the technical end. Most listed Taiwanese drugmakers compete on oral generics and exports of simple molecules; TTY competes on difficult injectables, liposomes and oncology - a much smaller field.

Domestic peers. The closest comparable in ambition and oncology focus is Lotus Pharmaceutical (美時, 1795) - the largest specialty-generic player in Taiwan by revenue, strong in oncology generics such as lenalidomide and aggressively export-oriented. The traditional broad-line generic houses - YSP / 永信 (3705, the volume leader in conventional generics), Standard Chem & Pharm / 生達 (1720), China Chemical & Pharmaceutical / 中化 (1701), and Nang Kuang / 南光 (1752, a sterile-injectable specialist) - overlap with TTY mainly in injectables and hospital channel rather than in liposomes or oncology in-licensing.

Where TTY wins and loses. Against the broad generic houses, TTY wins on the difficulty of its products - liposomes and oncology injectables they largely don't make - and on its oncology commercial franchise and in-licensing relationships. Against Lotus, the comparison is closer: Lotus is bigger and has a more developed US generic-oncology export machine, so TTY is the smaller player in scale but holds a distinctive liposome/CDMO capability and a stronger domestic oncology in-licensing book. Nang Kuang is the most direct rival in sterile injectables but lacks TTY's liposome platform and oncology depth. TTY's exposure is its sub-scale position internationally: in the global market for difficult generics and CDMO it is a minnow next to Indian and Western injectable specialists.

Barriers to entry. Genuinely high for the liposomal/sterile-injectable niche. A new entrant needs aseptic manufacturing, validated liposome process science, EU/FDA inspection clearance, and years of regulatory dossiers - a five-to-fifteen-year build, not a capex decision. The oncology salesforce and innovator relationships are a second, softer barrier. At the commodity oral-generic end, by contrast, barriers are low and margins commoditized - which is exactly why TTY avoids competing there.

Structural shifts. Two are relevant: rising global concern about supply-chain resilience for antibiotics and critical injectables (a tailwind for a credentialed domestic maker), and continued consolidation and price pressure in commodity generics (which pushes ambitious Taiwanese players, TTY included, toward differentiated and export segments).

Market caps are approximate peer-size references as of about June 2026 and move daily; they are not used for any valuation of TTY.

6. Industry

Demand drivers. TTY's demand is driven by structural healthcare needs rather than economic cycles: an ageing Taiwanese population (rising cancer and chronic-disease incidence), persistent hospital demand for critical-care anti-infectives, and growing global anxiety about secure supply of essential injectables and antibiotics. On the export side, demand is driven by global shortages of difficult-to-make sterile drugs - markets that periodically run short of products like amphotericin B or chemotherapy agents reward any qualified, inspection-cleared supplier.

Industry size and structure. Taiwan's domestic pharmaceutical market is mature and dominated by the NHI single-payer system, which constrains pricing and rewards cost-effective, reliable supply. Generics and difficult generics are the export ambition for Taiwanese firms; among listed companies, those exporting more than US$10m annually include Lotus (1795), China Chemical (1701), YSP (3705), Standard Chem (1720), Nang Kuang (1752), and TTY itself. The far larger prize is the global difficult-generic and sterile-injectable market, which is structurally short of qualified suppliers.

Where TTY sits in the supply chain. TTY is a finished-dose manufacturer and brand-holder, not an API maker - it formulates, fills and finishes complex injectables, and it both sells its own brands and contract-manufactures for others. In liposomes specifically it occupies a rare position in the global supply chain as one of relatively few FDA/EU-cleared liposomal sterile manufacturers.

Import substitution. Domestically, a major theme management invokes is reducing Taiwan's reliance on imported critical drugs - antibiotics and difficult injectables - by supplying them locally. Globally, the dynamic runs the other way: TTY substitutes for shortfalls in Western markets, exporting into the US where domestic supply of certain injectables is thin.

Regulatory environment. This is a heavily regulated industry where regulation is the moat: NHI listing and pricing govern the domestic market, and EU GMP / US FDA approvals gate exports. Each approval is slow and inspection-based, which limits new competition but also makes growth approval-paced rather than demand-paced.

Cyclicality. Low. Drug demand - especially oncology and critical care - is largely non-discretionary and acyclical. The cyclical elements are minor: vaccine demand is seasonal and tender-timing dependent, and export/CDMO revenue is lumpy because it follows regulatory approvals and contract wins rather than the macro cycle.

Tailwinds and headwinds. Tailwinds: ageing demographics, supply-resilience policy, and global injectable shortages. Headwinds: NHI price erosion on mature products, the slow grind of foreign regulatory approvals, and intensifying competition in any generic category that becomes attractive.

7. Growth triggers

All items below are drawn from the five investor conferences listed in Section 9. No historical figures are included.

• Two new product launches per year, sustained. Management committed to maintaining a cadence of at least two new product launches annually going forward (FY2025 conference, 2026-03-25; reiterated as a standing commitment by President Hou).

  Management framed future growth as resting on continued overseas-market deployment plus a steady cadence of new product launches (reported from the FY2025 conference, 2026-03-25).

• Pulmivex lung-cancer product, launched January 2026. A new domestic lung-cancer product positioned as a growth driver for 2026 (Q1 2026 conference, 2026-05-27; flagged as forthcoming at the FY2025 conference, 2026-03-25).

• Lipo-AB international roll-out beyond the US. With US share already above one-third, management guided new-market entries for Lipo-AB in Australia (regulatory approval pending), the Middle East and Southeast Asia, plus continued growth in South Korea (FY2025 conference, 2026-03-25; export expansion repeated across Q3 2025 and Q1 2026 conferences).

• Export ratio target above 20%. The individual-company export ratio rose to 18.8% by Q3 2025 from 13.7% in 2024, with management targeting a move above 20% (Q3 2025 conference, 2025-11-26; reiterated Q1 2026, 2026-05-27).

• Bobimixyn antibiotic ramp. A newly launched back-line antibiotic described as ramping quickly and addressing supply-resilience demand (Q3 2025 conference, 2025-11-26; momentum reaffirmed Q1 2026, 2026-05-27).

• In-licensed oncology additions reaching reimbursement. Minjuvi (tafasitamab) secured NHI reimbursement at end-2025, and Xpovio (selinexor) distribution rights were obtained - both expected to contribute as reimbursement-driven oncology volume builds (Q1 2026 conference, 2026-05-27).

• A second difficult generic entering the US market. Following Lipo-AB and arsenic trioxide, management pointed to a second difficult-to-formulate generic targeted for the US (FY2025 conference, 2026-03-25).

• OkaBIK varicella vaccine public-tender opportunity. Positioned to bid for Taiwan's public vaccination programme in Q4 2025, with potential deliveries from Q4 2026 if selected (Q1 2025 conference, 2025-05-27).

• CDMO mandates on the liposome/microsphere platform. Management continues to position the export & CDMO unit as the multi-year compounding layer, leveraging scarce liposome and microsphere manufacturing capability (GM commentary, FY2025 conference, 2026-03-25).

8. Key risks

Approval-paced growth (high probability, moderate drag). TTY's most important growth lever - export and CDMO - is gated by foreign regulatory approval. Each new-market Lipo-AB launch (Australia "pending," Middle East, Southeast Asia) waits on a regulator, and timelines slip for reasons outside the company's control. The mechanism: management can guide a launch, but until the dossier clears, there is no revenue, so the export ramp arrives in unpredictable steps rather than a smooth line. This is the single most likely source of a "good story, slow numbers" quarter.

Single-product concentration in the export thesis (medium probability, high impact on the growth narrative). A large share of the international story rests on one product, Lipo-AB, in one main market, the US. Any erosion of that >1/3 US share - a new entrant qualifying, a competitor resolving its own supply issues, or pricing pressure - would directly undercut the export ratio target that management has made central to the equity story.

NHI price erosion on the domestic base (high probability, moderate drag). Taiwan's single-payer system periodically cuts reimbursement prices on established drugs. Because much of TTY's domestic oncology and critical-care revenue is mature and NHI-reimbursed, ongoing price cuts are a persistent headwind that the company must outrun with volume and new launches.

In-licensing dependence (medium probability, moderate impact). A meaningful slice of the oncology unit is foreign innovator drugs distributed under licence (Yondelis, Pemazyre, Minjuvi, Xpovio). These relationships can be renegotiated, taken in-house by the innovator, or lost at renewal, and the economics are thinner than own-manufactured products. The reimbursement timing (Minjuvi's multi-quarter wait to end-2025) also shows how external gates control the pace.

Governance and key-person history (low probability now, but a real scar). The founder-era embezzlement case (Lin Jung-chin / Inopha AG / the diverted J&J contract fees, per Mirror Media and Business Today, 2020) is a reminder that this company has been damaged by insider self-dealing before. The installation of former Premier Lin Chuan as chairman was a deliberate credibility repair, and the controlling block sits with the Dawan Technology vehicle. Investors should treat related-party dealings and the controlling shareholder's intentions as a live monitoring item rather than a settled one.

Pledge ratio on the controlling stake (low-to-medium probability, tail risk). The largest reported holder, Dawan Technology, carries a high pledge ratio (~27%) on its shares. Pledged controlling stakes can amplify downside in a sharp share-price decline (forced-sale dynamics) and are a governance flag worth watching, even if benign in normal conditions.

Sub-scale internationally (structural). TTY is small relative to global injectable and CDMO players. In any category that becomes commercially attractive, larger, lower-cost competitors can enter, and TTY's defence is capability and certification rather than scale - a durable but not unlimited moat.

9. Walk the talk

The five conferences used (all confirmed via the company IR conference index and the poorstock earnings-call record):

1. Q1 2025 results - 2025-05-27 (KGI Securities)
2. Q2 / H1 2025 results - 2025-08-20 (Cathay Securities)
3. Q3 / 9M 2025 results - 2025-11-26 (Yuanta Securities)
4. FY2025 results - 2026-03-25 (Fubon Securities)
5. Q1 2026 results - 2026-05-27 (KGI Securities)

The most recent (2026-05-27) is within ~90 days of the report date. The underlying IR slide decks are image-based PDFs that could not be machine-read; the analysis below is built from the contemporaneous Taiwanese financial-press coverage of each conference (cnyes, udn, winvest, Genet, poorstock) cross-checked against the company's monthly revenue disclosures. Per the report's constraints I describe trajectories qualitatively rather than citing the underlying figures.

Across the cycle, management's central promise has been consistency: steady growth from two leg-supports (oncology in-licensing plus the export/CDMO ramp) and a disciplined cadence of new products. The track record over these five quarters supports the "does what they say" reading more than the "overpromises" reading.

Starting at Q1 2025 (2025-05-27), management framed the year around overseas deployment, the Lipo-AB US share story, the new antibiotic Bobimixyn, and a pipeline including the OkaBIK varicella vaccine bid and difficult-generic exports. The quarter itself was strong on a year-over-year basis, and management set expectations that growth would be carried by international expansion and new launches rather than the mature domestic base.

By Q2 / H1 2025 (2025-08-20) and especially Q3 / 9M 2025 (2025-11-26), the export thesis was visibly delivering: management could point to the individual-company export ratio rising from 13.7% in 2024 to 18.8% by Q3, with Lipo-AB gaining US share and Bobimixyn ramping after launch. The promise to grow the international mix was not just repeated - it was being evidenced quarter on quarter, and the company reported reaching record operating levels through nine months. This is the strongest stretch of "talk matched by walk" in the cycle.

At the FY2025 conference (2026-03-25), management restated the standing commitment to launch at least two new products per year and laid out the next wave of Lipo-AB markets (Australia pending, Middle East, Southeast Asia, continued Korea growth), a second difficult generic for the US, and the addition of Minjuvi (reimbursed at end-2025) and Xpovio to the oncology book.

Management's stated formula was to keep deploying into overseas markets and keep launching new products to drive future growth (reported from the FY2025 conference, 2026-03-25).

Then at Q1 2026 (2026-05-27), the proof points landed on schedule: Pulmivex (the new lung-cancer product) had launched in January 2026 as promised, Minjuvi had its reimbursement, Xpovio rights were secured, and the export ratio target was reiterated above 20%. The new-product cadence promised at the FY2025 conference was visibly being honoured one quarter later.

The one area to watch is the export geography expansion: Australia approval remains "pending," and the Middle East / Southeast Asia entries are guided rather than yet delivered, so the next test of management credibility is whether those new-market launches convert on the timelines implied.

Assessment: This is management that broadly does what it says. The commitments are specific (named products, named markets, a numeric export-ratio path, a launch-cadence pledge) and the near-term ones - Bobimixyn, Lipo-AB US share, Pulmivex, Minjuvi reimbursement - were delivered on or close to schedule across five consecutive conferences. The tone is consistent and modestly conservative rather than promotional. The unproven element is the next leg of export geography, which is approval-gated and therefore the fairest place to judge them next.

10. Shareholder friendliness index

Dividends. TTY pays only cash dividends and has raised them steadily. The cash dividend distributed in 2024 (on FY2023 earnings) was NT$3.5 per share; the dividend distributed in 2025 (on FY2024 earnings) was NT$4.2; and the company declared NT$4.5 for FY2025 (to be distributed in 2026) (Win投資 / statementdog dividend records; nstock). That is three consecutive years of increases, extending a record of unbroken dividends spanning roughly a quarter-century. The payout ratio has run in the ~70% range of earnings, which signals a deliberate policy of returning the large majority of profit to shareholders rather than hoarding it - consistent with a cash-generative, low-capital-intensity specialty-pharma model.

Buybacks and dilution. TTY is not a buyback company. A search of the exchange buyback register (via money-link's 庫藏股 record) and financial-press coverage shows the only treasury-share programme on record dates to August 2004, when the board authorised up to 4,000k shares and repurchased ~3,625k (about 90% of the authorisation, ~NT$166m, at an average ~NT$45.7) for employee-transfer purposes. No buyback programme was announced or executed in the last three years (2023-2025). Share count is essentially flat: paid-in capital is ~NT$2.487bn with ~248.65m shares outstanding, and because the company pays cash rather than stock dividends and issues only modest employee options, dilution over the three-year window is negligible. Capital return therefore comes entirely through the rising cash dividend, not buybacks.

Verdict: Returns Capital - a steadily rising cash dividend with a ~70% payout and a flat share count, offset only by the absence of buybacks.

11. Insider activities

Venue and source note. TTY trades on the Taipei Exchange (TPEx); the primary insider-disclosure source is Taiwan's Market Observation Post System (MOPS, mops.twse.com.tw - 董監事持股 / 內部人持股異動). Transaction-level insider filings on MOPS are served through forms that were not machine-readable within this search budget, and aggregator pages for 4105 returned encoding-garbled or blank content. Transaction-by-transaction insider buy/sell data for TTY over the last 12 months could not be reliably retrieved from the primary MOPS source or accessible aggregators within the search budget. What can be stated with confidence is the holding structure and the governance changes around it, drawn from board-holding records.

Ownership and board structure (from director-holding records):

• Controlling shareholder: Dawan Technology Co., Ltd. (大灣科技) is the largest holder, with ~24.1m shares - the controlling vehicle - carrying a high pledge ratio (~27.37%). This block is associated with the post-founder ownership camp (Hsiao Ying-chun became Dawan's board representative in 2018).
• Chairman: Lin Chuan (林全), former Premier of Taiwan, holds a small personal stake (~120,000 shares); he transitioned from being Dawan Technology's board representative to an individual director in November 2018 (at which point ~21.8m shares he had "represented" reverted to Dawan rather than being personally held).
• Vice Chairman: Zhang Wenhua (張文華), ~4.41m shares, unpledged.
• General Manager / President: Hou Ching-lan (侯靜蘭).
• Aggregate director and supervisor holding: ~11.34% of shares outstanding.

Buys and sells over the last 12 months. No open-market insider purchase or sale by a named director/officer of material size could be verified for the trailing 12 months from accessible sources. The board's aggregate holding (~11.34%) and the controlling Dawan block appear broadly stable, with no disclosed director election upheaval or major reported insider divestiture in the 2025-2026 window surfaced in the financial press.

Net assessment. With transaction-level data not retrievable, the honest read is neutral with one monitoring flag. There is no evidence of conviction insider buying (which would have been the strongest possible bullish signal) and no evidence of alarming insider selling. The one item that warrants ongoing attention is governance rather than trading: the controlling stake sits in a holding company (Dawan Technology) with a meaningful share-pledge ratio, in a company whose founder era ended in an embezzlement case. That is a "watch the related parties" flag, not a transactional red flag. A reader who needs the granular record should pull TTY's 內部人持股異動 directly from MOPS.

12. Scenarios

Bull case. The export and CDMO engine becomes the story. Lipo-AB clears its pending Australian approval and lands in the Middle East and Southeast Asia, while holding its dominant US share; the export ratio pushes through 20% and keeps climbing, turning TTY from a Taiwan-domestic drugmaker into a genuine regional specialty-injectable exporter. The two-new-products-a-year cadence keeps refreshing the oncology book - Pulmivex scales, Minjuvi and Xpovio build reimbursed volume, and a second difficult generic clears the US. The scarce liposome and microsphere platform starts winning CDMO mandates from international pharma, adding a higher-margin, stickier revenue layer on top of product sales. The Lin Chuan chairmanship and clean post-founder governance attract institutional ownership that the founder-era scandal had repelled. In two to three years TTY looks like a compounding specialty exporter with a credible global injectable franchise, not a slow-growth NHI-dependent generic house.

Base case. Management delivers roughly what it has guided. The domestic oncology and critical-care base grows modestly, fighting NHI price erosion with volume and new launches; the two-launches-a-year cadence holds; Lipo-AB keeps its US position and adds a market or two with the usual approval slippage. The export ratio grinds toward and perhaps past 20% but in lumpy, approval-paced steps rather than a smooth ramp. CDMO contributes occasional contract wins without yet becoming a large, predictable line. The cash dividend keeps rising in line with steadily growing profit. This is a steady, defensible, cash-returning specialty pharma that compounds quietly - the most probable path given the consistency management has shown across five conferences.

Bear case. The export thesis stalls where it is most concentrated. A competitor erodes Lipo-AB's US share or resolves its own supply problem, and the new-market approvals (Australia, Middle East, Southeast Asia) keep slipping, so the export ratio plateaus and the central growth narrative deflates. NHI price cuts grind down the mature domestic base faster than new launches replace it, and an in-licensed oncology drug is pulled back in-house by its innovator or lost at renewal, taking a chunk of oncology revenue with it. CDMO mandates that justify the "platform" story fail to materialise at scale against larger global competitors. In a sharper bear turn, the high pledge ratio on the controlling Dawan stake amplifies a share-price decline, and renewed scrutiny of related-party dealings reopens the governance wound that the Lin Chuan chairmanship was meant to close. The result is a flat-to-eroding domestic generic business with an export option that never fully delivered.

Notes on coverage and gaps

• Five conferences confirmed (2025-05-27, 2025-08-20, 2025-11-26, 2026-03-25, 2026-05-27); the most recent is within 90 days. IR slide decks are image-PDFs and were not machine-readable, so conference analysis relies on contemporaneous Taiwanese financial-press coverage cross-checked against monthly revenue disclosures.
• Insider transaction-level data could not be retrieved from MOPS or accessible aggregators within the search budget (Section 11); ownership structure is reported instead, with the limitation stated explicitly.
• Section 13 (Further Reading) is omitted: searches of SemiAnalysis, Stratechery, and MBI Deep Dives returned no coverage of TTY Biopharm, as expected for a Taiwan-listed specialty pharmaceutical company.

Sources:

• TTY Biopharm corporate site (English) / Chinese IR
• TTY oncology business unit (TOT)
• poorstock - TTY 4105 earnings-call records / board & major shareholders
• cnyes - Hou Ching-lan overseas strategy / 2 new products/year / Sept 2025 revenue
• winvest - TTY 4105 dividend & financials
• statementdog - dividend policy / monthly revenue
• wantgoo - dividend history
• stockanalysis.com - TTY 4105 overview
• nstock - TTY 4105 business profile
• money-link - buyback (庫藏股) register
• Mirror Media - Lin Jung-chin embezzlement case / Business Today - TTY lawsuit
• GeneOnline - Lin Jung-chin / CenterLab
• Sinotrade - Taiwan generic-drug exporter overview